Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 0.81 |
| ▸ | DRD2 | P14416 | 2/20 | 0.81 |
| ▸ | DRD4 | P21917 | 3/20 | 0.76 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896039 | 0.93 | SIGMAR1 (0.87) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL12673255 | 0.92 | SIGMAR1 (0.85) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL8284828 | 0.91 | SIGMAR1 (1.00) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL8285666 | 0.89 | SIGMAR1 (1.00) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL13638098 | 0.89 | SIGMAR1 (0.81) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL13631985 | 0.88 | SIGMAR1 (0.81) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL12673260 | 0.88 | SIGMAR1 (0.83) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL8285662 | 0.87 | SIGMAR1 (1.00) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL1883345 | 0.85 | SIGMAR1 (0.74) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL1884293 | 0.85 | SIGMAR1 (0.75) | SIGMAR1DRD3DRD2DRD4TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893266-B2 | Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers | WASHINGTON UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893266-B2 | Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers | WASHINGTON UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100028936-A1 | DETECTION OF CANCER CELLS IN VITRO USING SIGMA-2 RECEPTOR LIGANDS AS RADIOTRACERS | WASHINGTON UNIVERSITY (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028936-A1 | DETECTION OF CANCER CELLS IN VITRO USING SIGMA-2 RECEPTOR LIGANDS AS RADIOTRACERS | WASHINGTON UNIVERSITY (US) | 2010-02-04 | — | — | US | disclosed |
| US-7612206-B2 | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors | WASHINGTON UNIVERSITY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612206-B2 | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors | WASHINGTON UNIVERSITY (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090041663-A1 | SIGMA-2 RECEPTOR RADIOTRACERS FOR IMAGING THE PROLIFERATIVE STATUS OF SOLID TUMORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
| US-20090041663-A1 | SIGMA-2 RECEPTOR RADIOTRACERS FOR IMAGING THE PROLIFERATIVE STATUS OF SOLID TUMORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
| US-7390902-B2 | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors | WASHINGTON UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390902-B2 | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors | WASHINGTON UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2005048810-A2 | SIGMA-2 RECEPTOR RADIOTRACERS FOR IMAGING THE PROLIFERATIVE STATUS OF SOLID TUMORS | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041663-A1 | SIGMA-2 RECEPTOR RADIOTRACERS FOR IMAGING THE PROLIFERATIVE STATUS OF SOLID TUMORS | TMEM97, SIGMAR1, SSTR2 | SIGMAR1 2/4885DRD3 1949/4885DRD2 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.